Here are the S-1 registration statements from First Tracks Biotherapeutics, Inc. (TRAXV) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow TRAXV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAXV filings page.
First Tracks Biotherapeutics, Inc. is registering 10,497,054 shares of common stock for resale by existing stockholders under a Form S-1 registration statement. The company will not receive any proceeds from these resale transactions.
First Tracks was spun off from AnaptysBio, Inc. on April 20, 2026 and now trades on Nasdaq under the symbol TRAX, with a May 7, 2026 closing price of $17.82 per share. In a March 2026 private placement tied to the spin-off, First Tracks sold 5,791,479 primary shares and investors purchased 4,705,575 secondary shares at $13.81 per share, generating approximately $80 million in gross proceeds for the company.
First Tracks is a clinical-stage biotechnology company developing immunology therapeutics for autoimmune and inflammatory diseases, led by antibodies rosnilimab, ANB033 and ANB101. The business reported a 2025 net loss of $166.1 million and had $238.2 million in cash and cash equivalents as of December 31, 2025, and expects its existing cash, cash equivalents and investments to fund its current operating plan beyond the next 12 months. The company qualifies as an emerging growth company and a smaller reporting company, allowing reduced disclosure and compliance obligations.